Rani Therapeutics on Friday announced a licensing deal to develop and sell an oral version of Chugai Pharmaceutical's ...
Additions to sites in Cincinnati, Ohio, and Bend, Ore. broaden early development capabilities to help accelerate pre-clinical oral drug product innovation and advanced drug delivery CINCINNATI & BEND, ...
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
In a recent article published in Nature Communications, researchers performed a genomic investigation of oral resistome development, i.e., of genes that confer antimicrobial resistance (AMR). Since ...
Shares of Rani Therapeutics Holdings have doubled, to $1.12, in premarket trading after the company said it has entered into a collaboration and license agreement with Chugai Pharmaceutical.
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies ...
Mastering preventive pediatric dentistry can transform your child’s oral health for life—discover how to foster these ...
Veradermics raised $150 million to advance VDPHL01, an oral minoxidil treatment for hair regrowth, through Phase III trials ...
Shares of MIRA Pharmaceuticals climbed after the clinical stage development said its novel oral pharmaceutical marijuana analog normalized pain and reduced inflammation. The stock rose 61% to $2.13 ...
Peanut oral immunotherapy may help young children who are highly allergic to peanuts become desensitized to their allergy, or go into remission. The corresponding clinical trial was funded by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback